Fate Therapeutics Inc (OQ:FATE)

Mar 19, 2024 08:44 am ET
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to...
Mar 05, 2024 04:01 pm ET
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune...
Mar 01, 2024 08:00 am ET
Fate Therapeutics to Present at Upcoming March Investor Conferences
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to...
Feb 26, 2024 04:01 pm ET
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune...
Feb 15, 2024 08:00 am ET
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to...
Feb 02, 2024 04:01 pm ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune...
Jan 08, 2024 08:00 am ET
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune...
Dec 13, 2023 05:00 pm ET
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune...
Nov 08, 2023 04:01 pm ET
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune...
Nov 03, 2023 09:00 pm ET
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders following a class action complaint that was filed...
Nov 02, 2023 02:58 pm ET
SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Ardelyx, Inc., Leslie’s, Inc., Enovix Corporation, and Fate Therapeutics, Inc. If you are a current owner of shares of any of these stocks,...
Oct 25, 2023 08:00 am ET
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to...
Sep 09, 2023 07:00 pm ET
Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, Inc. (NASDAQ: FATE), National Vision Holdings, Inc. (NASDAQ: EYE)
Sotera Health Co. (NASDAQ: SHC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company’s made false and misleading representations...
Aug 31, 2023 08:00 am ET
Fate Therapeutics to Present at Upcoming September Investor Conferences
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to...
Aug 27, 2023 09:00 pm ET
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders following a class action complaint that was filed...
Aug 21, 2023 01:53 pm ET
SHAREHOLDER ALERT: Morris Kandinov Investigating FATE, HAFC, PEGA, and CVNA; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Fate Therapeutics, Inc., Hanmi Financial Corporation, Pegasystems Inc., and Carvana Co.   If you are a current owner of shares of any of these...
Aug 08, 2023 04:01 pm ET
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune...
Jul 28, 2023 08:00 am ET
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to...
Jun 30, 2023 10:50 pm ET
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fate Therapeutics, Inc. (NasdaqGM: FATE).
Jun 21, 2023 11:07 pm ET
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders following a class action complaint that was filed against Fate on January 20, 2023 with a Class Period from April 2, 2020 to January 5, 2023. Our investigation concerns whether the board of directors of Fate have breached their fiduciary duties to the company.
Jun 16, 2023 10:50 pm ET
FATE THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fate Therapeutics, Inc. (NasdaqGM: FATE). On April 2, 2020, the...
Jun 10, 2023 08:11 pm ET
Lifshitz Law PLLC Announces Investigations of PRTK, CIR, REUN, and FATE
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of PRTK to Gurnet Point Capital and Novo Holdings A/S for $2.15 per share in cash, plus...
Jun 08, 2023 09:00 pm ET
Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders following a class action complaint that was filed against Fate on January 20, 2023 with a Class Period from April 2, 2020 to January 5, 2023. Our investigation concerns whether the board of directors of Fate have breached their fiduciary duties to the company.
Jun 05, 2023 11:33 am ET
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fate Therapeutics, Inc. (NasdaqGM: FATE).
May 31, 2023 08:00 am ET
Fate Therapeutics to Present at Upcoming June Investor Conferences
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to...
May 03, 2023 04:01 pm ET
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune...
May 02, 2023 09:16 am ET
Investigation Alert Caribou, Fate Therapeutics, Globe Life, Norfolk Southern: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Caribou Biosciences, Inc. (NASDAQ: CRBU) Johnson Fistel, LLP is investigating potential claims on behalf of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) against certain of its officers and directors. If you are a...
May 02, 2023 09:16 am ET
Investigation Alert Caribou, Fate Therapeutics, Globe Life, Norfolk Southern: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Caribou Biosciences, Inc. (NASDAQ: CRBU) Johnson Fistel, LLP is investigating potential claims on behalf of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) against certain of its officers and directors. If you are a...
Apr 24, 2023 08:00 am ET
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to...
Mar 30, 2023 12:03 pm ET
Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, Inc. (NASDAQ: FATE), Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), and International Business Machines Cor
Sotera Health Co. (NASDAQ: SHC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company’s made false and misleading representations...
Mar 22, 2023 11:35 am ET
FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Cl
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2023.
Mar 22, 2023 10:30 am ET
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fate Therapeutics, Inc. (FATE) Investors of Class Action and Last Few Hours to Actively Participate
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) and certain of its officers, on behalf of all persons...
Mar 22, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)
NEW YORK, March 22, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fate Therapeutics, Inc..
Mar 21, 2023 09:00 pm ET
FATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). Investors have until March 22, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Mar 21, 2023 06:50 pm ET
FATE IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has already...
Mar 21, 2023 11:40 am ET
FATE FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm’s Attorneys, Mar. 22nd Deadline Pending in Securiti
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023Lead Plaintiff Deadline: Mar. 22, 2023Visit:...
Mar 21, 2023 10:30 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
The Law Offices of Frank R. Cruz reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ:
Mar 21, 2023 05:45 am ET
FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders
NEW YORK, March 21, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE) alleging that the Company violated federal securities laws.
Mar 20, 2023 01:04 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).   The class action, filed in the United States District Court for the...
Mar 20, 2023 12:05 pm ET
DEADLINE ALERT for YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 20, 2023 10:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fate Therapeutics, Inc. (“Fate” or...
Mar 20, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fate Investors of a Lead Plaintiff Deadline of March 22, 2023
NEW YORK, March 20, 2023 /PRNewswire/ -- Attention Fate Therapeutics, Inc. ("Fate") (NASDAQ: FATE) shareholders:
Mar 17, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Fate Therapeutics, Inc. (NASDAQ: FATE), Sotera Health Co. (NASDAQ: SHC), Argo...
Mar 17, 2023 04:06 pm ET
RYVYL Inc.: Please contact the Portnoy Law Firm to recover your losses; April 3, 2023 deadline
The Portnoy Law Firm advises RYVYL Inc. (“RYVYL” or the “Company”) f/k/a GreenBox POS (NASDAQ: RVYL) investors that a lawsuit filed on behalf of investors that purchased Fate securities (NASDAQ: FATE) between April 2, 2020 through January 5, 2023...
Mar 17, 2023 10:00 am ET
FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., March 17, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE).
Mar 17, 2023 05:45 am ET
FATE SHAREHOLDER ALERT: Jakubowitz Law Reminds Fate Shareholders of a Lead Plaintiff Deadline of March 22, 2023
NEW YORK, March 17, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE).
Mar 16, 2023 09:15 pm ET
6-Day Deadline Alert: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fate Therapeutics, Inc. ("Fate" or "the Company") (NASDAQ:FATE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Mar 16, 2023 04:08 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has already...
Mar 16, 2023 12:39 pm ET
FATE 6-DAY DEADLINE ALERT: Hagens Berman Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm’s Attorneys Before Mar. 22nd Deadline in Securities Class Action
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023Lead Plaintiff Deadline: Mar. 22, 2023Visit:...
Mar 16, 2023 05:45 am ET
FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 16, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) of a class action securities lawsuit.
Mar 15, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)
NEW YORK, March 15, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fate Therapeutics, Inc..
Mar 14, 2023 08:48 pm ET
DEADLINE ALERT for YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 14, 2023 05:45 am ET
FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders
NEW YORK, March 14, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE) alleging that the Company violated federal securities laws.
Mar 13, 2023 03:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE
NEW YORK, March 13, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE). The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv-111-WQH-NLS, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"), seeking to recover
Mar 13, 2023 12:24 pm ET
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 13, 2023 11:00 am ET
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fate Therapeutics, Inc. (FATE) Investors of Class Action and Last Few Days to Actively Participate
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Mar 13, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fate Investors of a Lead Plaintiff Deadline of March 22, 2023
NEW YORK, March 13, 2023 /PRNewswire/ -- Attention Fate Therapeutics, Inc. ("Fate") (NASDAQ: FATE) shareholders:
Mar 12, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Fate Therapeutics, Inc. (NASDAQ:...
Mar 11, 2023 04:16 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm’s Attorneys Before Mar. 22nd Deadline in Securities Class Action
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023Lead Plaintiff Deadline: Mar. 22, 2023Visit:...
Mar 10, 2023 01:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE). The class action, filed in the United States District Court for the...
Mar 10, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 10, 2023 09:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fate Therapeutics, Inc. (“Fate” or...
Mar 09, 2023 07:55 pm ET
Fate Therapeutics, Inc.: Please contact the Portnoy Law Firm to recover your losses; March 22, 2023 deadline
The Portnoy Law Firm advises Fate Therapeutics, Inc (“Fate” or “the Company”) (NASDAQ: FATE) investors that a lawsuit filed on behalf of investors that purchased Fate securities (NASDAQ: FATE) between April 2, 2020 through January 5, 2023 (the...
Mar 09, 2023 08:00 am ET
FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES, March 9, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE).
Mar 09, 2023 04:45 am ET
FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 9, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) of a class action securities lawsuit.
Mar 08, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)
NEW YORK, March 8, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fate Therapeutics, Inc..
Mar 07, 2023 02:17 pm ET
Fate Therapeutics, Inc. (FATE) Lead Deadline Approaching: Contact Robbins LLP for Information Regarding the Class Action against Fate Therapeutics, Inc.
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired shares of Fate Therapeutics, Inc. (NASDAQ: FATE) common stock between April 2, 2020 and January 5,...
Mar 07, 2023 12:00 pm ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 07, 2023 12:00 am ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That Securities Class Action Lawsuits Have Been Filed on Behalf of Investors in Fate Therapeutics Inc. (FATE), National Vision Holdings, Inc. (EYE
The law firm of Kirby McInerney LLP reminds investors that securities class action lawsuits have been filed on behalf of investors in securities of Fate Therapeutics Inc., National Vision Holdings, Inc., PLDT Inc., and Y-mAbs Therapeutics, Inc....
Mar 06, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IBM, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of International Business Machines Corporation (NYSE: IBM), Fate Therapeutics, Inc....
Mar 06, 2023 05:16 pm ET
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has already...
Mar 06, 2023 04:01 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Fate Therapeutics (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Fraud Class Action
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023Lead Plaintiff Deadline: Mar. 22, 2023Visit:...
Mar 06, 2023 11:50 am ET
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 04, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 03, 2023 04:01 pm ET
Fate Therapeutics to Present at Upcoming March Investor Conferences
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to...
Mar 03, 2023 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fate Therapeutics, Inc. (“Fate” or...
Mar 01, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Fate Therapeutics, Inc. (NASDAQ: FATE), Sotera Health Co. (NASDAQ: SHC), Argo...
Mar 01, 2023 01:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).   The class action, filed in the United States District Court for the...
Mar 01, 2023 01:00 pm ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 28, 2023 04:01 pm ET
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune...
Feb 28, 2023 12:15 pm ET
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 28, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 27, 2023 04:42 pm ET
FATE SHAREHOLDER NOTICE: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023Lead Plaintiff Deadline: Mar. 22, 2023Visit:...
Feb 27, 2023 10:00 am ET
FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Feb. 27, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE).
Feb 27, 2023 04:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fate Investors of a Lead Plaintiff Deadline of March 22, 2023
NEW YORK, Feb. 27, 2023 /PRNewswire/ -- Attention Fate Therapeutics, Inc. ("Fate") (NASDAQ: FATE) shareholders:
Feb 24, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Fate Therapeutics, Inc. (NASDAQ: FATE), Sotera Health Co. (NASDAQ: SHC), Argo...
Feb 24, 2023 04:44 pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FATE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has already...
Feb 24, 2023 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fate Therapeutics, Inc. (“Fate” or...
Feb 23, 2023 06:54 pm ET
SHAREHOLDER UPDATE: Y-mAbs Therapeutics, Bioventus Inc, Fate Therapeutics, Inc, and Invivyd Inc: Johnson Fistel Encourages Shareholders to Seek Counsel for Class Action Lawsuits
Shareholder rights law firm Johnson Fistel, LLP announces that class action lawsuits have commenced on behalf of investors of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Bioventus Inc. (NASDAQ: BVS), and Fate Therapeutics, Inc. (NASDAQ: FATE), and...
Feb 23, 2023 11:00 am ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 22, 2023 11:49 am ET
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 22, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 21, 2023 04:45 am ET
FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders
NEW YORK, Feb. 21, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE) alleging that the Company violated federal securities laws.
Feb 20, 2023 06:19 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE). The class action, filed in the United States District Court for the...
Feb 20, 2023 10:00 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Fate Therapeutics (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Fraud Class Action
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023Lead Plaintiff Deadline: Mar. 22, 2023Visit:...
Feb 19, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IBM, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of International Business Machines Corporation (NYSE: IBM), Fate Therapeutics, Inc....
Feb 19, 2023 01:18 pm ET
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has...
Feb 17, 2023 12:00 pm ET
FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES, Feb. 17, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE).
Feb 16, 2023 10:00 am ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 16, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 15, 2023 02:59 pm ET
Fate Therapeutics, Inc. (FATE) Class Action: Contact Robbins LLP for Information Regarding the Class Action and Lead Plaintiff Deadline
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired shares of Fate Therapeutics, Inc. (NASDAQ: FATE) common stock between April 2, 2020 and January 5,...
Feb 15, 2023 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fate Therapeutics, Inc. (“Fate” or...
Feb 14, 2023 06:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).   The class action, filed in the United States District Court for the...
Feb 14, 2023 12:45 pm ET
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 14, 2023 04:45 am ET
FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders
NEW YORK, Feb. 14, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE) alleging that the Company violated federal securities laws.
Feb 13, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Fate Therapeutics, Inc. (NASDAQ: FATE), Sotera Health Co. (NASDAQ: SHC), Argo...
Feb 13, 2023 03:25 pm ET
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has...
Feb 13, 2023 11:19 am ET
FATE INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023Lead Plaintiff Deadline: Mar. 22, 2023Visit:...
Feb 13, 2023 08:00 am ET
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to...
Feb 13, 2023 06:10 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE).  The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv-111-WQH-NLS, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"), seeking to recover
Feb 13, 2023 04:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fate Investors of a Lead Plaintiff Deadline of March 22, 2023
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Attention Fate Therapeutics, Inc. ("Fate") (NASDAQ: FATE) shareholders:
Feb 10, 2023 04:45 am ET
FATE SHAREHOLDER ALERT: Jakubowitz Law Reminds Fate Shareholders of a Lead Plaintiff Deadline of March 22, 2023
NEW YORK, Feb. 10, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE).
Feb 09, 2023 05:57 pm ET
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fate Therapeutics Inc. (FATE) Investors and Encourages Investors to Contact the Firm Before March 22, 2023
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Fate Therapeutics, Inc. (“Fate”) (NASDAQ: FATE) securities...
Feb 09, 2023 02:46 pm ET
Fate Therapeutics, Inc. (FATE) Class Action Alert: Contact Robbins LLP for Information Regarding the Class Action Against Fate Therapeutics, Inc.
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired shares of Fate Therapeutics, Inc. (NASDAQ: FATE) common stock between April 2, 2020 and January 5,...
Feb 09, 2023 12:15 pm ET
DEADLINE ALERT for FATE, SHC, ARBK, and EYE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 09, 2023 10:00 am ET
FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES, Feb. 9, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE).
Feb 09, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 09, 2023 04:45 am ET
FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) of a class action securities lawsuit.
Feb 08, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bioventus Inc. (NASDAQ: BVS), ESS Tech, Inc. (NYSE: GWH, GWH.WT), International...
Feb 08, 2023 05:22 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FATE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has...
Feb 08, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)
NEW YORK, Feb. 8, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fate Therapeutics, Inc..
Feb 07, 2023 12:00 pm ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 07, 2023 10:56 am ET
Class Action Deadlines: Y-mAbs Therapeutics, Bioventus Inc, Fate Therapeutics, Inc, and Invivyd Inc – Contact Johnson Fistel
Shareholder rights law firm Johnson Fistel, LLP announces that class action lawsuits have commenced on behalf of investors of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Bioventus Inc. (NASDAQ: BVS), and Fate Therapeutics, Inc. (NASDAQ: FATE), and...
Feb 07, 2023 04:45 am ET
FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders
NEW YORK, Feb. 7, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE) alleging that the Company violated federal securities laws.
Feb 06, 2023 11:05 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE
NEW YORK, Feb. 7, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE). The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv-111-WQH-NLS, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"), seeking to recover da
Feb 06, 2023 10:00 pm ET
FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Feb. 6, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE).
Feb 06, 2023 03:53 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023Lead Plaintiff Deadline: Mar. 22, 2023Visit:...
Feb 04, 2023 06:19 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).   The class action, filed in the United States District Court for the...
Feb 03, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bioventus Inc. (NASDAQ: BVS), ESS Tech, Inc. (NYSE: GWH, GWH.WT), International...
Feb 03, 2023 02:00 pm ET
DEADLINE ALERT for FATE, SHC, ARBK, and EYE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 03, 2023 04:45 am ET
FATE SHAREHOLDER ALERT: Jakubowitz Law Reminds Fate Shareholders of a Lead Plaintiff Deadline of March 22, 2023
NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE).
Feb 02, 2023 05:19 pm ET
Fate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fate Therapeutics, Inc.
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired shares of Fate Therapeutics, Inc. (NASDAQ: FATE) common stock between April 2, 2020 and January 5, 2023, for violations of the Securities Exchange Act of 1934. Fate is a clinical-stag
Feb 02, 2023 10:37 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 02, 2023 09:46 am ET
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, issued an open...
Feb 02, 2023 04:45 am ET
FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Feb. 2, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) of a class action securities lawsuit.
Feb 01, 2023 07:13 pm ET
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fate Therapeutics, Inc. (FATE) Investors and Encourages Investors to Contact the Firm Before March 22, 202
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Fate Therapeutics, Inc. (“Fate”) (NASDAQ: FATE) securities during the period from April 2, 2020 through January 5, 2023 (the “Class Pe
Feb 01, 2023 09:45 am ET
FATE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fate Therapeutics, Inc. (NASDAQ: FATE) securities between April 2, 2020 and January 5, 2023, inclusive (the “Class Period”) have until March 22, 2023 to seek...
Feb 01, 2023 09:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Fate Therapeutics, Inc. (FATE) Investors of Class Action and to Actively Participate
NEW YORK, Feb. 1, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/fate.
Feb 01, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)
NEW YORK, Feb. 1, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fate Therapeutics, Inc..
Jan 31, 2023 02:43 pm ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 31, 2023 04:45 am ET
FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders
NEW YORK, Jan. 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE) alleging that the Company violated federal securities laws.
Jan 30, 2023 04:10 pm ET
NOTICE: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – FATE
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fate Therapeutics, Inc. (NASDAQ: FATE) securities between April 2, 2020 and January 5, 2023, inclusive (the “Class Period”) have until March 22, 2023 to seek appointment as lead plaintiff
Jan 30, 2023 03:43 pm ET
FATE CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023Lead Plaintiff Deadline: Mar. 22, 2023Visit:...
Jan 30, 2023 04:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fate Investors of a Lead Plaintiff Deadline of March 22, 2023
NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Attention Fate Therapeutics, Inc. ("Fate") (NASDAQ: FATE) shareholders:
Jan 29, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FATE, and Sotera and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Fate Therapeutics, Inc. (NASDAQ: FATE), and Sotera Health Co. (NASDAQ: SHC)....
Jan 29, 2023 02:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).   The class action, filed in the United States District Court for the...
Jan 28, 2023 01:02 pm ET
INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FATE
SAN DIEGO, Jan. 28, 2023 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fate Therapeutics, Inc. (NASDAQ: FATE) securities between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period") have until March 22, 2023 to seek appointment as lead plaintiff in the Fate Therapeutics class action lawsuit. Captioned Hadian v. Fate Therapeutics, Inc., No. 23-cv-00111 (S.D. Cal.), the Fate Therapeutics class action lawsuit charges Fate Therapeutics and certain of its top executives with violations of the Securities Exchange Act of 1934.
Jan 27, 2023 06:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE
NEW YORK, Jan. 27, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE). The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv-111-WQH-NLS, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"), seeking to recover d
Jan 27, 2023 05:23 pm ET
Fate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Against Fate Therapeutics, Inc.
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired shares Fate Therapeutics, Inc. (NASDAQ: FATE) common stock between April 2, 2020 and January 5, 2023,...
Jan 27, 2023 02:33 pm ET
DEADLINE ALERT for YMAB, FATE, and SHC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 27, 2023 08:30 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fate Therapeutics, Inc. ("Fate" or "the Company") (NASDAQ:FATE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jan 27, 2023 04:45 am ET
FATE SHAREHOLDER ALERT: Jakubowitz Law Reminds Fate Shareholders of a Lead Plaintiff Deadline of March 22, 2023
NEW YORK, Jan. 27, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE).
Jan 26, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ:
Jan 26, 2023 04:45 am ET
FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) of a class action securities lawsuit.
Jan 25, 2023 12:00 pm ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
Law Offices of Howard G. Smith reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) securities between April 2, 2020 and January 5, 2023, inclusive (the “Class Period”).
Jan 25, 2023 10:10 am ET
INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fate Therapeutics Class Action Lawsuit – FATE
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fate Therapeutics, Inc. (NASDAQ: FATE) securities between April 2, 2020 and January 5, 2023, inclusive (the “Class Period”) have until March 22, 2023 to seek appoint
Jan 25, 2023 09:46 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fate Therapeutics, Inc. ("Fate" or "the Company") (NASDAQ:FATE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jan 24, 2023 07:08 pm ET
Fate Therapeutics, Inc.: Please contact the Portnoy Law Firm to recover your losses; March 22, 2023 deadline.
The Portnoy Law Firm advises Fate Therapeutics, Inc (“Fate” or “the Company”) (NASDAQ: FATE) investors that a lawsuit filed on behalf of investors that purchased Fate securities (NASDAQ: FATE) between April 2, 2020 through January 5, 2023 (the...
Jan 24, 2023 06:19 pm ET
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fate Therapeutics Inc. (FATE) Investors and Encourages Investors to Contact the Firm Before March 22, 2023
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Fate Therapeutics, Inc. (“Fate”) (NASDAQ: FATE) securities...
Jan 24, 2023 01:29 pm ET
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fate Therapeutics, Inc. (FATE)
The Class: Robbins LLP informs shareholders that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired shares Fate Therapeutics, Inc. (NASDAQ: FATE) common stock between April 2, 2020 and January 5, 2023, for violations of the Securities Exchange Act of 1934. Fate is a clinical-stag
Jan 24, 2023 12:00 pm ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ:
Jan 24, 2023 11:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Fate Therapeutics, Inc. (FATE) Investors of Class Action and to Actively Participate
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Jan 24, 2023 08:30 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fate Therapeutics, Inc. (“Fate” or “the Company”) (NASDAQ:
Jan 23, 2023 09:00 pm ET
FATE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). Investors have until March 22, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jan 23, 2023 06:12 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ:
Jan 23, 2023 05:22 pm ET
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Fate Therapeutics, Inc. (“Fate”) (NASDAQ: FATE) securities during the period from April 2, 2020 through January 5, 2023 (the “Class Pe
Jan 23, 2023 03:39 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5, 2023Lead Plaintiff Deadline: Mar. 22, 2023Visit:...
Jan 23, 2023 02:46 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) securities between April 2, 2020 and January 5, 2023, inclusive (the “Class Period”). Fate investors have until March 22, 2023 to file a lead plaintif
Jan 23, 2023 11:19 am ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. (FATE)
Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased the securities of Fate...
Jan 23, 2023 10:56 am ET
Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline
Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Fate Therapeutics Inc. (“Fate” or the “Company”) for violations of the federal securities laws on...
Jan 23, 2023 10:03 am ET
EQUITY ALERT: Rosen Law Firm Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2023.
Jan 23, 2023 09:29 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fate Therapeutics, Inc. (“Fate” or “the Company”) (NASDAQ:
Jan 22, 2023 04:33 pm ET
Fate Therapeutics Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Fate Therapeutics Inc. (“Fate” or “the Company”) (NASDAQ: FATE) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Fate investors...
Jan 21, 2023 02:30 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action Against Certain Officers and Directors of Fate Therapeutics, Inc.  – FATE
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).   The class action, filed in the United States District Court for the...
Jan 19, 2023 11:00 am ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ:
Jan 18, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), Super Micro, Inc. (NASDAQ: SMCI), and Fate Therapeutics, Inc. (NASDAQ: FATE)....
Jan 18, 2023 05:25 pm ET
FATE INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Secur
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Visit: https://www.hbsslaw.com/investor-fraud/FATE Contact An Attorney Now: [email protected] 844-916-0895 Fate...
Jan 18, 2023 02:46 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
Law Offices of Howard G. Smith continues its investigation on behalf of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) investors concerning the Company’s possible violations of federal securities laws.
Jan 17, 2023 05:49 pm ET
The Law Offices of Frank R. Cruz Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
The Law Offices of Frank R. Cruz continues its investigation of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ:
Jan 11, 2023 09:05 pm ET
FATE ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Fate Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) on behalf of Fate stockholders. Our investigation concerns whether Fate has violated the federal securities laws and/or engaged in other unlawful business practices.
Jan 11, 2023 04:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ:
Jan 11, 2023 03:00 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) investors concerning the Company’s possible violations of federal securities laws.
Jan 11, 2023 02:09 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ:
Jan 10, 2023 06:01 pm ET
HAGENS BERMAN, National Trial Attorneys, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations
Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now. Visit: https://www.hbsslaw.com/investor-fraud/FATE Contact An Attorney Now: [email protected]...
Jan 09, 2023 09:00 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fate Therapeutics, Inc. (“Fate” or “the Company”) (NASDAQ:
Jan 06, 2023 06:02 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fate Therapeutics, Inc. (“Fate” or “the Company”) (NASDAQ:
Jan 06, 2023 09:35 am ET
Fate Therapeutics Shareholder Investigation: Submit Your Losses to Johnson Fistel
Shareholder rights law firm Johnson Fistel, LLP is investigating whether Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate” or the “Company), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely...
Jan 05, 2023 08:00 pm ET
FATE Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Potential Securities Claims Against Fate Therapeutics, Inc.
The law firm of Wohl & Fruchter LLP is investigating whether Fate Therapeutics, Inc. (Nasdaq: FATE) (“FATE”) violated federal securities laws in connection with the sudden termination of its collaboration and option agreement with Janssen Biotech,...
Jan 05, 2023 05:00 pm ET
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune...
Dec 13, 2022 08:00 am ET
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, presented preclinical data of several novel strategies designed to...
Dec 12, 2022 07:30 am ET
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology's 64th Annual Meeting (ASH 2022). The presentation highlights the potential of a novel dual antigen targeting approach...
Dec 10, 2022 02:46 pm ET
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today presented interim clinical data from the dose-escalation stage of...
Dec 10, 2022 10:00 am ET
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today presented interim clinical data from the dose-escalation stage of...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.